ACADIA Pharmaceuticals Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
ACADIA Pharmaceuticals Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does ACADIA Pharmaceuticals Inc. do? Business model and key facts
Get the full picture of ACADIA Pharmaceuticals Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 653
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Stocks related to ACADIA Pharmaceuticals Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting ACADIA Pharmaceuticals Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
ACADIA Pharmaceuticals Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
